Rare Disease Report Staff

FDA will no longer require Genzyme to continue the Risk Evaluation and Mitigation Strategy program.

Caregivers give thoughts on attributes they are looking for in DMD treatment.

FDA updates guidelines to expedite the development and review of new drugs.